Trial reportAnnals of the rheumatic diseases2010
The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial.
Trial report in Annals of the rheumatic diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Calcium channel blockers for primary and secondary Raynaud's phenomenon.The Cochrane database of systematic reviews · 2017Pooled it
- An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in SSc-related RP.Rheumatology (Oxford, England) · 2025Trial
- The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial.Rheumatology (Oxford, England) · 2023Trial
- Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2022Trial
- The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.Arthritis care & research · 2013Trial
- Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.The Journal of rheumatology · 2011Trial
- Minimally important differences of the gout impact scale in a randomized controlled trial.Rheumatology (Oxford, England) · 2011Trial
- Effects of Audio-Guided Imagery on Raynaud Phenomenon in Connective Tissue Disease.ACR open rheumatology · 2025Article
- Evaluation of the choroidal vascularity index and choroidal thickness in patients with systemic sclerosis.International ophthalmology · 2025Article
- Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study.Clinical rheumatology · 2025Article
- Review
- Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets.RMD open · 2024Observational
- Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis.ACR open rheumatology · 2023Article
- Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon.Arthritis research & therapy · 2023Article
- Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Patient-reported outcome instruments in clinical trials of systemic sclerosis.Journal of scleroderma and related disorders · 2020Review
- The patient experience of Raynaud's phenomenon in systemic sclerosis.Rheumatology (Oxford, England) · 2019Review
- Pharmacotherapy Options in the Management of Raynaud's Phenomenon.Current treatment options in rheumatology · 2018Article
- A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systems.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe Raynaud's condition score (RCS) is a validated outcome measure for Raynaud's phenomenon (RP).
objectiveTo assess the minimally important difference (MID) and patient acceptable symptom state (PASS) for RCS in patients with RP. SUBJECTS: and methods Patients with active RP (n=162) (mean RCS >25 (0-100 visual analogue scale) participated in a placebo-controlled, crossover randomised clinical trial (RCT). Data from the two treatment groups were combined for this analysis. Retrospective and prospective anchors were administered during the RCT. MID groups were defined as the group who reported being somewhat better (anchor #1) and a one-step change from "unbearable" to "very severe", etc (anchor #2). Patients were considered to have achieved PASS if they rated their Raynaud's condition as "very mild" or "mild" at the last study visit.
resultsThe mean age of participants was 48.9 years and the mean baseline RCS was 46.4 points. The RCS change score for the MID improvement group ranged from -13.9 to -14.3 points and PASS estimate was 34.0 points.
conclusionThe MID and PASS estimates for RCS are 14-15 points for improvement and 34 points, respectively, on a 0-100 scale in a large RCT of patients with active RP. This information can aid in interpreting RCS in future RP trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.